Clinical and pharmacological correlates of caffeine consumption in subjects with schizophrenia – Data from the FACE-SZ cohort - Université Paris Cité Accéder directement au contenu
Article Dans Une Revue Journal of Psychiatric Research Année : 2023

Clinical and pharmacological correlates of caffeine consumption in subjects with schizophrenia – Data from the FACE-SZ cohort

Résumé

Caffeine is the most consumed psychoactive substance worldwide. Previous studies suggested higher caffeine consumption in subjects with schizophrenia spectrum disorders (SSD) as well as associations with symptoms, medication and medication side-effects. In a large and well-characterized sample of SSD subjects we explored the association between caffeine consumption and clinical (psychosis related, severity, general health) as well as pharmacological (antipsychotic treatment, sedation potential) variables. Eight hundred four subjects with data on their caffeine (coffee and tea) consumption successively recruited were included in this study. After controlling for potential confounders (demographic variables, smoking) only the negative dimension of psychosis was associated with the amount of caffeine ingested. Less severe negative symptoms were associated with higher caffeine consumption. The effect size of this association was small (partial correlation coefficient = −0.12) but significant.
Fichier non déposé

Dates et versions

hal-04068684 , version 1 (14-04-2023)

Identifiants

Citer

Andreï Szoke, Jean Romain Richard, Guillaume Fond, David Misdrahi, Mohamed Lajnef, et al.. Clinical and pharmacological correlates of caffeine consumption in subjects with schizophrenia – Data from the FACE-SZ cohort. Journal of Psychiatric Research, 2023, 161, pp.206-212. ⟨10.1016/j.jpsychires.2023.03.017⟩. ⟨hal-04068684⟩
30 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More